Primary hyperparathyroidism in adults-(Part II) surgical management and postoperative follow-up: Position statement of the Endocrine Society of Australia, The Australian & New Zealand Endocrine Surgeons, and The Australian & New Zealand Bone and Mineral Society.
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
19 Dec 2021
19 Dec 2021
Historique:
revised:
29
10
2021
received:
31
08
2021
accepted:
02
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
21
12
2021
Statut:
aheadofprint
Résumé
To develop evidence-based recommendations to guide the surgical management and postoperative follow-up of adults with primary hyperparathyroidism. Representatives from relevant Australian and New Zealand Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing eight key questions. Diagnostic imaging does not determine suitability for surgery but can guide the planning of surgery in suitable candidates. First-line imaging includes ultrasound and either parathyroid 4DCT or scintigraphy, depending on local availability and expertise. Minimally invasive parathyroidectomy is appropriate in most patients with concordant imaging. Bilateral neck exploration should be considered in those with discordant/negative imaging findings, multi-gland disease and genetic/familial risk factors. Parathyroid surgery, especially re-operative surgery, has better outcomes in the hands of higher volume surgeons. Neuromonitoring is generally not required for initial surgery but should be considered for re-operative surgery. Following parathyroidectomy, calcium and parathyroid hormone levels should be re-checked in the first 24 h and repeated early if there are risk factors for hypocalcaemia. Eucalcaemia at 6 months is consistent with surgical cure; parathyroid hormone levels do not need to be re-checked in the absence of other clinical indications. Longer-term surveillance of skeletal health is recommended. This position statement provides up-to-date guidance on evidence-based best practice surgical and postoperative management of adults with primary hyperparathyroidism.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016;151(10):959-968.
Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-3569.
Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10):3607-3618.
Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3570-3579.
Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-3594.
National Institute for Health and Care Excellence. Hyperparathyroidism (primary): diagnosis, assessment and initial management. Nice Guideline [NG 132]; 2019. https://www.nice.org.uk/guidance/ng132/chapter/Recommendations#diagnostic-testing-in-primary-care
Fervers B, Burgers JS, Haugh MC, et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care. 2006;18(3):167-176.
Ahmadieh H, Kreidieh O, Akl EA, El-Hajj Fuleihan G. Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults. Cochrane Database Syst Rev. 2020;10:CD010787.
Greenspan BS, Dillehay G, Intenzo C, et al. SNM practice guideline for parathyroid scintigraphy 4.0. J Nucl Med Technol. 2012;40(2):111-118.
Wale DJVB, Wong K, Gross MD. Parathyroid adenoma evaluation utilizing SPECT/CT imaging. J Am Osteop Coll Radiol. 2018;7(1):18-25.
Hu J, Ngiam KY, Parameswaran R. Mediastinal parathyroid adenomas and their surgical implications. Ann R Coll Surg Engl. 2015;97(4):259-261.
Kedarisetty S, Fundakowski C, Ramakrishnan K, Dadparvar S. Clinical value of Tc99m-MIBI SPECT/CT versus 4D-CT or US in management of patients with hyperparathyroidism. Ear Nose Throat J. 2019;98(3):149-157.
Neumann DR, Obuchowski NA, Difilippo FP. Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med. 2008;49(12):2012-2017.
Kao A, Shiau YC, Tsai SC, Wang JJ, Ho ST. Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression. Eur J Nucl Med Mol Imaging. 2002;29(8):1012-1015.
Rausch I, Fuchsel FG, Kuderer C, Hentschel M, Beyer T. Radiation exposure levels of routine SPECT/CT imaging protocols. Eur J Radiol. 2016;85(9):1627-1636.
Czarnecki CA, Einsiedel PF, Phal PM, Miller JA, Lichtenstein M, Stella DL. Dynamic CT for parathyroid adenoma detection: how does radiation dose compare with nuclear medicine? Am J Roentgenol. 2018;210(5):1118-1122.
Beland MD, Mayo-Smith WW, Grand DJ, Machan JT, Monchik JM. Dynamic MDCT for localization of occult parathyroid adenomas in 26 patients with primary hyperparathyroidism. Am J Roentgenol. 2011;196(1):61-65.
Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006;140(6):932-940.
Yeh R, Tay YD, Tabacco G, et al. Diagnostic performance of 4D CT and Sestamibi SPECT/CT in localizing parathyroid adenomas in primary hyperparathyroidism. Radiology. 2019;291(2):469-476.
O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med. 1992;33(3):313-318.
Abdulla AG, Ituarte PH, Harari A, Wu JX, Yeh MW. Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10 years. Ann Surg. 2015;261(4):746-750.
Chen H, Wang TS, Yen TW, et al. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg. 2010;252(4):691-695.
Mitchell J, Milas M, Barbosa G, Sutton J, Berber E, Siperstein A. Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. Surgery. 2008;144(6):899-906.
Erinjeri NJ, Udelsman R. Volume-outcome relationship in parathyroid surgery. Baillieres Best Pract Res Clin Endocrinol Metab. 2019;33(5):101287.
McGill J, Sturgeon C, Kaplan SP, Chiu B, Kaplan EL, Angelos P. How does the operative strategy for primary hyperparathyroidism impact the findings and cure rate? A comparison of 800 parathyroidectomies. J Am Coll Surg. 2008;207(2):246-249.
Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235(5):665-670.
Malmaeus J, Granberg PO, Halvorsen J, Akerstrom G, Johansson H. Parathyroid surgery in Scandinavia. Acta Chir Scand. 1988;154(7-8):409-413.
Iacobone M, Scerrino G, Palazzo FF. Parathyroid surgery: an evidence-based volume-outcomes analysis: European Society of Endocrine Surgeons (ESES) positional statement. Langenbecks Arch Surg. 2019;404(8):919-927.
Jinih M, O'Connell E, O'Leary DP, Liew A, Redmond HP. Focused versus bilateral parathyroid exploration for primary hyperparathyroidism: a systematic review and meta-analysis. Ann Surg Oncol. 2017;24(7):1924-1934.
Kiernan CM, Wang T, Perrier ND, Grubbs EG, Solorzano CC. Bilateral neck exploration for sporadic primary hyperparathyroidism: use patterns in 5,597 patients undergoing parathyroidectomy in the collaborative endocrine surgery quality improvement program. J Am Coll Surg. 2019;228(4):652-659.
Khokar AM, Kuchta KM, Moo-Young TA, Winchester DJ, Prinz RA. Increasing trend of bilateral neck exploration in primary hyperparathyroidism. Am J Surg. 2020;219(3):466-470.
Norman J, Lopez J, Politz D. Abandoning unilateral parathyroidectomy: why we reversed our position after 15,000 parathyroid operations. J Am Coll Surg. 2012;214(3):260-269.
Carchman E, Ogilvie J, Holst J, Yim J, Carty S. Appropriate surgical treatment of lithium-associated hyperparathyroidism. World J Surg. 2008;32(10):2195-2199.
Arora A, Garas G, Tolley N. Robotic parathyroid surgery: current perspectives and future considerations. ORL J Otorhinolaryngol Relat Spec. 2018;80(3-4):195-203.
Sasanakietkul T, Carling T. Primary hyperparathyroidism treated by transoral endoscopic parathyroidectomy vestibular approach (TOEPVA). Surg Endosc. 2017;31(11):4832-4833.
Harrison BJ, Triponez F. Intraoperative adjuncts in surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2009;394(5):799-809.
Li J, Vasilyeva E, Hiebert J, Britton H, Walker B, Wiseman SM. Limited clinical utility of intraoperative frozen section during parathyroidectomy for treatment of primary hyperparathyroidism. Am J Surg. 2019;217(5):893-898.
Badii B, Staderini F, Foppa C, et al. Cost-benefit analysis of the intraoperative parathyroid hormone assay in primary hyperparathyroidism. Head Neck. 2017;39(2):241-246.
Najafian A, Kahan S, Olson MT, Tufano RP, Zeiger MA. Intraoperative PTH may not be necessary in the management of primary hyperparathyroidism even with only one positive or only indeterminate preoperative localization studies. World J Surg. 2017;41(6):1500-1505.
Sartori PV, Saibene AM, Leopaldi E, et al. Intraoperative parathyroid hormone testing in primary hyperparathyroidism surgery: time for giving up? Eur Arch Otorhinolaryngol. 2019;276(1):267-272.
Norlén O, Wang KC, Tay YK, et al. No need to abandon focused parathyroidectomy: a multicenter study of long-term outcome after surgery for primary hyperparathyroidism. Ann Surg. 2015;261(5):991-996.
Inabnet WB, Kim CK, Haber RS, RA L. Radioguidance is not necessary during parathyroidectomy. Arch Surg. 2002;137(8):967-970.
Ito F, Sippel R, Lederman J, Chen H. The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg. 2007;245(6):959-963.
Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery. 2004;136(6):1310-1322.
Ling Y, Zhao J, Zhao Y, Li K, Wang Y, Kang H. Role of intraoperative neuromonitoring of recurrent laryngeal nerve in thyroid and parathyroid surgery. J Int Med Res. 2020;48(9):300060520952646.
Iorio O, Petrozza V, De Gori A, et al. Parathyroid autotransplantation during thyroid surgery. Where we are? A systematic review on indications and results. J Invest Surg. 2019;32(7):594-601.
Demarchi MS, Karenovics W, Bedat B, Triponez F. Intraoperative autofluorescence and indocyanine green angiography for the detection and preservation of parathyroid glands. J Clin Med. 2020;9(3):18.
Guerrero MA, Evans DB, Lee JE, et al. Viability of cryopreserved parathyroid tissue: when is continued storage versus disposal indicated? World J Surg. 2008;32(5):836-839.
Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr. 2002;41(6):258-263.
Locker FG, Silverberg SJ, Bilezikian JP. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med. 1997;102(6):543-550.
Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005;90(4):2122-2126.
Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic crisis: a clinical review. Am J Med. 2015;128(3):239-245.
Schweitzer VG, Thompson NW, Harness JK, Nishiyama RH. Management of severe hypercalcemia caused by primary hyperparathyroidism. Arch Surg. 1978;113(4):373-381.
Chopra P, Mitra S. Patients with symptomatic primary hyperparathyroidism: an anaesthetic challenge. Indian J Anaesth. 2009;53(4):492-495.
Rajeev P, Stechman MJ, Kirk H, Gleeson FV, Mihai R, Sadler GP. Safety and efficacy of minimally-invasive parathyroidectomy (MIP) under local anaesthesia without intra-operative PTH measurement. Int J Surg. 2013;11(3):275-277.
Rago R, Forfori F, Frustaci G, et al. Day case parathyroidectomy: is this the right way for the patients? Gland Surg. 2020;9(suppl 1):S6-S13.
Denizot A, Pucini M, Chagnaud C, Botti G, Henry JF. Normocalcemia with elevated parathyroid hormone levels after surgical treatment of primary hyperparathyroidism. Am J Surg. 2001;182(1):15-19.
Lo Gerfo P. Bilateral neck exploration for parathyroidectomy under local anesthesia: a viable technique for patients with coexisting thyroid disease with or without sestamibi scanning. Surgery. 1999;126(6):1011-1014.
Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70(2):114-119.
Stewart ZA, Blackford A, Somervell H, et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005;138(6):1018-1025.
Kald BA, Heath DI, Lausen I, Mollerup CL. Risk assessment for severe postoperative hypocalcaemia after neck exploration for primary hyperparathyroidism. Scand J Surg. 2005;94(3):216-220.
Guillen Martinez AJ, Smilg Nicolas C, Moraleda Deleito J, Guillen Martinez S, Garcia-Purrinos Garcia F. Risk factors and evolution of calcium and parathyroid hormone levels in hungry bone syndrome after parthyroidectomy for primary hyperparathyroidism. Endocrinol Diabetes Nutr (Engl Ed). 2020;67(5):310-316.
Vasher M, Goodman A, Politz D, Norman J. Postoperative calcium requirements in 6,000 patients undergoing outpatient parathyroidectomy: easily avoiding symptomatic hypocalcemia. J Am Coll Surg. 2010;211(1):49-54.
Westerdahl J, Lindblom P, Valdemarsson S, Tibblin S, Bergenfelz A. Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Arch Surg. 2000;135(2):142-147.
Jakubauskas M, Beiša V, Strupas K. Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism. Acta Med Litu. 2018;25(1):45-51.
Kaya C, Tam AA, Dirikoç A, et al. Hypocalcemia development in patients operated for primary hyperparathyroidism: Can it be predicted preoperatively? Archives of endocrinology and metabolism. 2016;60(5):465-471.
Hypocalcaemia. In eTG complete [digital]. March 2021 ed. Therapeutic Guidelines Limited; 2019.
Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236(5):543-551.
Chen H, Sokoll LJ, Udelsman R. Outpatient minimally invasive parathyroidectomy: a combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay. Surgery. 1999;126(6):1016-1021.
Wang TS, Pasieka JL, Carty SE. Techniques of parathyroid exploration at North American endocrine surgery fellowship programs: what the next generation is being taught. Am J Surg. 2014;207(4):527-532.
Burkey SH, van Heerden JA, Thompson GB, Grant CS, Schleck CD, Farley DR. Reexploration for symptomatic hematomas after cervical exploration. Surgery. 2001;130(6):914-920.
Cao S, Hu Y, Zhao Y, et al. A retrospective study of elevated post-operative parathormone in primary hyperparathyroid patients. Oncotarget. 2017;8(60):101158-101164.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97(4):1153-1158.
Lou I, Balentine C, Clarkson S, Schneider DF, Sippel RS, Chen H. How long should we follow patients after apparently curative parathyroidectomy? Surgery. 2017;161(1):54-61.
Hedback G, Oden A. Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism. Eur J Endocrinol. 2003;148(4):413-421.
Hessman O, Stålberg P, Sundin A, et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg. 2008;32(5):774-781.
Grant CS, van Heerden JA, Charboneau JW, James EM, Reading CC. Clinical management of persistent and/or recurrent primary hyperparathyroidism. World J Surg. 1986;10(4):555-565.
Richards ML, Thompson GB, Farley DR, Grant CS. Reoperative parathyroidectomy in 228 patients during the era of minimal-access surgery and intraoperative parathyroid hormone monitoring. Am J Surg. 2008;196(6):937-942.
Karakas E, Müller HH, Schlosshauer T, Rothmund M, Bartsch DK. Reoperations for primary hyperparathyroidism-improvement of outcome over two decades. Langenbecks Arch Surg. 2013;398(1):99-106.
Wirowski D, Goretzki PE, Schwarz K, Lammers BJ, Dotzenrath C, Röher HD. Failed surgery in primary hyperparathyroidism-what has changed with time. Exp Clin Endocrinol Diabetes. 2013;121(6):323-328.
Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg. 1996;224(3):308-320.
Billings PJ, Milroy EJ. Reoperative parathyroid surgery. Br J Surg. 1983;70(9):542-546.
Thompson GB, Grant CS, Perrier ND, et al. Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Arch Surg. 1999;134(7):699-705.
Mariette C, Pellissier L, Combemale F, Quievreux JL, Carnaille B, Proye C. Reoperation for persistent or recurrent primary hyperparathyroidism. Langenbecks Arch Surg. 1998;383(2):174-179.
Patow CA, Norton JA, Brennan MF. Vocal cord paralysis and reoperative parathyroidectomy. A prospective study. Ann Surg. 1986;203(3):282-285.
Feingold DL, Alexander HR, Chen CC, et al. Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas. Surgery. 2000;128(6):1103-1110.
Acar N, Haciyanli M, Coskun M, et al. Diagnostic value of four-dimensional computed tomography and four-dimensional magnetic resonance imaging in primary hyperparathyroidism when first-line imaging was inadequate. Ann R Coll Surg Engl. 2020;102(4):294-299.
Solorzano CC, Lee TM, Ramirez MC, Carneiro DM, Irvin GL. Surgeon-performed ultrasound improves localization of abnormal parathyroid glands. Am Surg. 2005;71(7):557-563.
Witteveen JE, Kievit J, van Erkel AR, Morreau H, Romijn JA, Hamdy NAT. The role of selective venous sampling in the management of persistent hyperparathyroidism revisited. Eur J Endocrinol. 2010;163(6):945-952.
Patel SG, Saunders ND, Jamshed S, Weber CJ, Sharma J. Multimodal preoperative localization improves outcomes in reoperative parathyroidectomy: a 25-year surgical experience. Am Surg. 2019;85(9):939-943.
Lee NC, Norton JA. Multiple-gland disease in primary hyperparathyroidism: a function of operative approach? Arch Surg. 2002;137(8):896-900.
McKenzie TJ, Lo CY, Van Heerden JA. Parathyroid reoperations. In: Clark OH, Duh Q, Kebebew E, Gosnell J, Shen W, eds. Textbook of Endocrine Surgery. 3rd ed. Jaypee Brothers Medical Publishers; 2016:889-900.
Wojtczak B, Sutkowski K, Kaliszewski K, Barczyński M, Bolanowski M. Thyroid reoperation using intraoperative neuromonitoring. Endocrine. 2017;58(3):458-466.
Yen TWF, Wang TS, Doffek KM, Krzywda EA, Wilson SD. Reoperative parathyroidectomy: an algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results in a successful focused approach. Surgery. 2008;144(4):611-621.
van Heerden JA, Weiland LH, ReMine WH, Walls JT, Purnell DC. Cancer of the parathyroid glands. Arch Surg. 1979;114(4):475-480.
Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156(5):1132-1144.
Liu J, Zhan WW, Zhou JQ, Zhou W. Role of ultrasound in the differentiation of parathyroid carcinoma and benign parathyroid lesions. Clin Radiol. 2020;75(3):179-184.
Agarwal G, Dhingra S, Mishra SK, Krishnani N. Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch Surg. 2006;391(6):623-626.
Spinelli C, Bonadio AG, Berti P, Materazzi G, Miccoli P. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest. 2000;23(4):255-257.
Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110(2):255-264.
Hsu KT, Sippel RS, Chen H, Schneider DF. Is central lymph node dissection necessary for parathyroid carcinoma? Surgery. 2014;156(6):1336-1341.
Lloyd R, Osamura R, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. IARC Press; 2017.
Williams M, DeLellis R, Erickson L, et al. Parathyroid Carcinoma & Atypical Parathyroid Neoplasm Histopathology Reporting Guide. International Collaboration on Cancer Reporting; 2019.
Gill AJ. Understanding the genetic basis of parathyroid carcinoma. Endocr Pathol. 2014;25(1):30-34.
Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006;30(9):1140-1149.
Turchini J, Gill AJ. Hereditary parathyroid disease: sometimes pathologists do not know what they are missing. Endocr Pathol. 2020;31:218-230.
Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009;94(2):434-441.
Gill AJ, Lim G, Cheung VKY, et al. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) parathyroid tumors demonstrate distinctive morphologic features. Am J Surg Pathol. 2019;43(1):35-46.
Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):441.
Kruijff S, Sidhu SB, Sywak MS, Gill AJ, Delbridge LW. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2014;21(2):426-433.
Juhlin CC, Nilsson IL, Johansson K, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol. 2010;21(3):166-177.
Juhlin CC, Nilsson IL, Lagerstedt-Robinson K, et al. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. Modern Pathol. 2019;32(8):1082-1094.
Williams MD, DeLellis RA, Erickson LA, et al. Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110:73-82.
Landry C, Wang T, Asare E. Parathyroid. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017.
Betea D, Bradwell AR, Harvey TC, et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab. 2004;89(7):3413-3420.
Bukowski RM, Sheeler L, Cunningham J, Esselstyn C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med. 1984;144(2):399-400.
Calandra DB, Chejfec G, Foy BK, Lawrence AM, Paloyan E. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery. 1984;96(6):1132-1137.
Erovic BM, Goldstein DP, Kim D, et al. Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck. 2013;35(1):35-39.
Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98(11):2378-2384.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538-544.
Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer: an update. Cancer Treat Rev. 2020;86:102012.
Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16(4):724-731.
Christakis I, Silva AM, Kwatampora LJ, et al. Oncologic progress for the treatment of parathyroid carcinoma is needed. J Surg Oncol. 2016;114(6):708-713.
Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93(9):3462-3470.